Related Experiment Videos
[Chemotherapeutic effect on metastatic tumors]
1Dept. of Clinical Cancer Chemotherapy, Tohoku University.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|April 1, 1989
Summary
Induced Hypertension Chemotherapy (IHC) improved gastric cancer treatment outcomes by enhancing drug delivery to tumors. While IHC showed higher response rates for primary lesions and lymph node metastases, further study is needed for liver metastases.
Area of Science:
- Oncology
- Medical Chemistry
- Pharmacology
Context:
- Advanced gastric cancer presents significant treatment challenges.
- Conventional chemotherapy regimens have shown limited efficacy.
- Selective drug delivery to tumor sites is a key area of research.
Purpose:
- To evaluate the efficacy of Induced Hypertension Chemotherapy (IHC) in advanced gastric cancer.
- To compare IHC with conventional chemotherapy in terms of response rates.
- To investigate the mechanism of selective drug delivery to tumor tissues.
Summary:
- Patients with advanced gastric cancer received chemotherapy with or without Induced Hypertension Chemotherapy (IHC).
- IHC, which selectively increases blood flow to tumors using angiotensin II, was combined with adriamycin (ADR), 5-FU, and mitomycin C (MMC).
- Response rates for primary lesions and lymph node metastases were significantly higher with IHC, but liver metastases showed no statistical difference.
Impact:
- IHC demonstrates potential for enhancing chemotherapy effectiveness in gastric cancer, particularly for primary and lymph node metastatic lesions.
- The findings support the experimental mechanism of selective drug delivery to tumor tissues.
- Further research is warranted to optimize IHC for liver metastases and improve overall treatment outcomes.